Neoplastic Transformation of Human Mesenchymal Stromal Cells Mediated via LIN28B.
Antibiotics, Antineoplastic
/ pharmacology
Cell Line
Cell Movement
/ genetics
Cell Proliferation
/ genetics
Cell Transformation, Neoplastic
/ genetics
Cohort Studies
Datasets as Topic
Disease-Free Survival
Doxorubicin
/ pharmacology
Drug Resistance, Neoplasm
/ genetics
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
HMGA2 Protein
/ genetics
Humans
Kaplan-Meier Estimate
Mesenchymal Stem Cells
/ metabolism
MicroRNAs
/ metabolism
RNA-Binding Proteins
/ genetics
Sarcoma
/ drug therapy
Up-Regulation
Xenograft Model Antitumor Assays
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 05 2019
30 05 2019
Historique:
received:
24
10
2018
accepted:
20
05
2019
entrez:
1
6
2019
pubmed:
31
5
2019
medline:
24
10
2020
Statut:
epublish
Résumé
Bone marrow stromal (Mesenchymal) stem cells (MSCs) are multipotent bone cells capable of differentiating into mesoderm-type cells, such as osteoblasts and adipocytes. Existing evidence suggests that transformation of MSCs gives rise to sarcoma. In order to identify the molecular mechanism leading to spontaneous transformation of human bone marrow MSCs (hBMSCs), we performed comprehensive microRNA (miRNA) and mRNA profiling in the transformed hBMSC-Tum line compared to the parental clone. As a result, we identified multiple dysregulated molecular networks associated with the hBMSC transformed phenotype. LIN28B was upregulated 177.0-fold in hBMSC-Tum, which was associated with marked reduction in LET-7 expression and upregulated expression of its target HMGA2. Targeted depletion of LIN28B or exogenous expression of LET-7b suppressed hBMSC-Tum proliferation, colony formation, and migration. On the other hand, forced expression of LIN28B promoted malignant transformation of parental hBMSC cells as shown by enhanced in vitro colony formation, doxorubicin resistance, and in vivo tumor formation in immunocompromised mice. Analysis of LIN28B and HMGA2 expression levels in cohorts from The Cancer Genome Atlas sarcoma dataset revealed a strong inverse-relationship between elevated expression and overall survival (OS) in 260 patients (p = 0.005) and disease-free survival (DFS) in 231 patients (p = 0.02), suggesting LIN28B and HMGA2 are important regulators of sarcoma biology. Our results highlight an important role for the LIN28B/LET-7 axis in human sarcoma pathogenesis and suggest that the therapeutic targeting of LIN28B may be relevant for patients with sarcoma.
Identifiants
pubmed: 31147574
doi: 10.1038/s41598-019-44536-1
pii: 10.1038/s41598-019-44536-1
pmc: PMC6542832
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
HMGA2 Protein
0
HMGA2 protein, human
0
LIN28B protein, human
0
MicroRNAs
0
RNA-Binding Proteins
0
mirnlet7 microRNA, human
0
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8101Références
Mod Pathol. 2007 Jul;20(7):749-59
pubmed: 17464315
Stem Cells. 2011 Mar;29(3):397-403
pubmed: 21425403
J Clin Oncol. 1998 Apr;16(4):1248-55
pubmed: 9552022
Cell. 2011 Nov 23;147(5):1066-79
pubmed: 22118463
Oncotarget. 2012 Dec;3(12):1641-52
pubmed: 23482325
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
JAMA. 2009 Jul 15;302(3):261-75
pubmed: 19602686
Genes Dev. 2013 Oct 15;27(20):2233-45
pubmed: 24142874
Cancer Cell Int. 2016 Sep 29;16:77
pubmed: 27708551
Cell. 2009 Aug 21;138(4):696-708
pubmed: 19703396
Oncogene. 2004 Jun 24;23(29):5095-8
pubmed: 15107831
Trends Cell Biol. 2012 Sep;22(9):474-82
pubmed: 22784697
Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6139-44
pubmed: 21444814
Oncogene. 2008 Mar 27;27(14):2015-26
pubmed: 17922033
Oncotarget. 2016 Jun 14;7(24):35789-35802
pubmed: 27119506
Cell Death Dis. 2015 Jan 22;6:e1614
pubmed: 25611389
Stem Cell Rev Rep. 2013 Feb;9(1):32-43
pubmed: 22529014
J Clin Oncol. 1993 Jul;11(7):1269-75
pubmed: 8315424
Nat Genet. 2009 Jul;41(7):843-8
pubmed: 19483683
Oncotarget. 2018 Feb 5;9(17):13551-13564
pubmed: 29568377
Cancer. 2009 Oct 15;115(20):4795-806
pubmed: 19593798
Cancer Res. 2005 Apr 15;65(8):3126-35
pubmed: 15833842
Cell. 2009 Nov 13;139(4):693-706
pubmed: 19878981
Nature. 2009 Dec 3;462(7273):595-601
pubmed: 19898493
Nucleic Acids Res. 2014 Jan;42(Database issue):D92-7
pubmed: 24297251
Nat Biotechnol. 2002 Jun;20(6):592-6
pubmed: 12042863
Cancer Res. 2005 Oct 15;65(20):9226-35
pubmed: 16230383
Int J Cancer. 2012 Apr 15;130(8):1787-97
pubmed: 21618519
Genet Med. 2017 Aug;19(8):955-958
pubmed: 28125078
Diagn Mol Pathol. 1995 Sep;4(3):162-73
pubmed: 7493135
Nucleic Acids Res. 2016 May 5;44(8):3845-64
pubmed: 26917013
Oncol Rep. 2015 Apr;33(4):1723-30
pubmed: 25633261
Cell Res. 2012 Jan;22(1):62-77
pubmed: 21931359